Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

Upstream enters IPO queue; Nuvalent follow-on balloons to $575M

Also in BioCentury’s weekly Public Equity Report: Ascendis follows up a data release with a $300M offering; BioAge proposes terms for listing

September 20, 2024 8:20 PM UTC

Last week’s trio of biotech IPOs signaled that demand continues to exist for a certain class of companies: those with mid-to-late-stage assets that have generated clinical data, and experienced management teams to guide them along.

Joining the queue this week was Upstream Bio Inc., which filed late Wednesday to list on NASDAQ. The biotech ticks some key boxes: Its lead asset, verekitug, is in Phase II testing for severe asthma and chronic rhinosinusitis with nasal polyps; it has generated proof-of-concept data in a Phase Ib study; and its chairman and its CEO have held key roles at biotechs as they steered toward billion-dollar acquisitions...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article